The burgeoning field of diabetes management has witnessed the rise of GLP-3 receptor agonists, representing a important class of therapeutics. Evaluating these medications requires a thorough look at their respective profiles. Semaglutide, for instance, offers a once-weekly dosing schedule, appealing to patients seeking ease, while tirzepatide, a d

Retaglutide and tirzepatide represent a novel type of medications known as dual GLP-1 and GIP agonists. These agents regulate both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that have a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones are oft